## **Primary Care HEDIS Measures**

		HEDIS 2014?		Specification File
Key	Population Health Measures			'
1 BSC	Breast Cancer Screening	Υ	Υ	Breast_Cancer_Screening.pdf
2 CCS	Cervical Cancer Screening	Υ		Cervical_Cancer_Screen.pdf
CHL	Chlamydia Screening	Υ		Chlamydia_Screen.pdf
3	Age 16 - 20			
4	Age 21 - 24 Overall			
5 COL	Colorectal Cancer Screening	Υ	Υ	Colorectal_Cancer_Screen.pdf
CIS	Childhood Immunization Status	Υ		
6	Chicken Pox Vaccine			Chicken Pox Vaccine.pdf
7	Diphtheria Tetanus Pertussis Vaccine			Diphtheria-Tetanus-Pertussis_Vaccine.pdf
8	Hepatitis B Vaccine			Hepatitis_B_Vaccine.pdf
9	H Influenza Type B Vaccine			H_Influenza_TypeB_Vaccine.pdf
10	Measles Mumps Rubella Vaccine			Measles-Mumps-Rubella_Vaccine.pdf
11	Pneumococcal Conjugate Vaccine			Pneumococcal_Conjugate_Vaccine.pdf
12	Polio Vaccine			Polio_Vaccine.pdf
	Well-Child Visits			
13 W15	Well-Child Visits in the First 15 Months of Life	Υ		Well-Child Visits in the First 15 Months of Life.pdf
14 W34	Well-Child Visits in the 3 - 6 Years of Life	Υ		Well-Child Visits in the Third Fourth Fifth.pdf
15 AWC	Adolescent Well Care Visits	Υ		Adolescent Well-Care Visits.pdf
	Managing Chronic Conditions			
	Comprehensive Diabetes Care			09_CDC_Spec.pdf
16 CDC-H1C	Hemoglobin A1c (HbA1c) Testing	Υ		Diabetes_HbA1c_Test.pdf
17	HbA1C Good Control (<7%)	Υ	Υ	
18	HbA1C Adequate Control (<8%)	Υ	Υ	Diabetes-HbA1c_LessThan_8percent.pdf
19	HbA1C Poor Control (>9%)	Υ	Υ	
20 CDC-EE	Eye Exam (Retinal)	Υ	Υ	Diabetes-Eye_Exam.pdf

	CDC-LDL	Cholesterol Management for Patient with Diabete	S		
21	L	LDL-C Testing	Υ	Υ	Diabetes-Lipid_Test.pdf
22	2	LDL-C Control (<100 mg/dl)	Υ	Υ	Diabetes-LDL-C_LessThan_100mg.pdf
23	CDC-MAN	Medical Attention for Nephropathy	Υ	Υ	Diabetes-Microalbumin_Test.pdf
		Blood Pressure Management for Patient with			Comprehensive Diabetes Care- Blood Pressure
	CDC-BPC		Υ		Control- 2014 (CDC-BP).pdf
24		Blood Pressure Testing	Υ		
25		<140/90 mmHg	Υ		
26	5	<140/80 mmHg	Υ		
		Additional Chronic Care Measure			
	ASM	Asthma Medication Management	Υ		Asthma Medication Management.pdf
27	7	Age 5 - 11			
28	3	Age 12 - 18			
29	)	Age 19 - 50			
30	)	Age 51 - 64			
		Overall			
		Cholesterol Management for Patient with			
	CMC	Cardiovascular Conditions	Υ	Υ	
31	L	LDL-C Testing	Υ	Υ	CAD_Event-Cholesterol_Test.pdf
32	2	LDL-C Control (<100 mg/dl)	Υ	Υ	CAD-LDL-C_Less_than_100mg.pdf
		Annual Monitoring for Patients on Persistent			
	MPM	Medication	Υ	Υ	
33	3	ACE Inhibitors or ARBs			AnnualMonitoring-ACE_ARB_Drugs.pdf
34	l .	Digoxin			AnnualMonitoring-Digoxin.pdf
35	5	Diuretics			AnnualMonitoring-Diuretics.pdf
36		Anticonvulsants Carbamazepine			AnnualMonitoring-Anticonvulsant-Carbamazepine.pdf
37		Anticonvulsants Phenobarbital			AnnualMonitoring-Anticonvulsant-Phenobarbital.pdf
38		Anticonvulsants Phenytoin			AnnualMonitoring-Anticonvulsant-Phenytoin.pdf
39	)	Anticonvulsants Valproic Acid			AnnualMonitoring-Anticonvulsant-Valproic_Acid.pdf
		Overall			
		Other Measures			
40	CWP	Appropriate Testing for Children with Pharyngitis	Υ		Pharyngitis Treatment-Children.pdf
		Appropriate Treatment for Children with Upper			, <u>, , , , , , , , , , , , , , , , , , </u>
41	URI	Repiratory Infection	Υ		${\tt URI\_Treatment\_Without\_Antibiotics-Children.pdf}$

	Avoidance of Antibiotics Treatment in Adults with			
42 AAB	Acute Bronchitis	Υ	Acute_Bronchitis_Tx_Without_Antibiotics.pdf	
43 LBP	Use of Imaging Studies for Low Back Pain	Υ	Low_Back_Pain_Imaging_Studies.pdf	

Age group	USA 100% (percent of the population)			
Population	308 745 538	Age	% population	
0-4	20 201 362 (6.5%)	0-4	6.5	65
9-May	20 348 657 (6.6%)	5-9	6.6	131
14-Oct	20 677 194 (6.7%)	10-14	6.7	198
15-19	22 040 343 (7.1%)	15-19	7.1	269
20-24	21 585 999 (7.0%)	20-24	7	339
25-29	21 101 849 (6.8%)	25-29	6.8	407
30-34	19 962 099 (6.5%)	30-34	6.5	472
35-39	20 179 642 (6.5%)	35-39	6.5	537
40-44	20 890 964 (6.8%)	40-44	6.8	605
45-49	22 708 591 (7.4%)	45-49	7.4	679
50-54	22 298 125 (7.2%)	50-54	7.2	751
55-59	19 664 805 (6.4%)	55-59	6.4	815
60-64	16 817 924 (5.4%)	60-64	5.4	869
65-69	12 435 263 (4.0%)	65-69	4	909
70-74	9 278 166 (3.0%)	70-74	3	939
75-79	7 317 795 (2.4%)	75-79	2.4	963
80-84	5 743 327 (1.9%)	80-84	1.9	982
85+	5 493 433 (1.8%)	85+	1.8	1000

0.2588996764



